Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05439772 · ClinicalTrials.gov registry record · Phase 4

Examining the Effect of Ondansetron on Bowel Prep Success

A Phase 4 study of Weight Loss and Inflammatory Bowel Diseases, sponsored by State University of New York - Downstate Medical Center.

Completed
Registry status
Phase 4
Development phase
41
Enrollment target
1
Study location

NCT05439772 is a Phase 4 study of Weight Loss and Inflammatory Bowel Diseases that has completed, run by State University of New York - Downstate Medical Center. The registered enrollment target is 41 participants, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05439772, a Phase 4 study of Weight Loss and Inflammatory Bowel Diseases, has completed, sponsored by State University of New York - Downstate Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
41 participants
Enrollment target
1
Study location

Study Summary

This is a pilot randomized-controlled trial assessing the utility of ondansetron for improving pediatric pre-colonoscopy bowel prep outcomes using the boston bowel preparation score, as well as assessing the impact on patient experience of bowel preparation.

Interventions

  • DRUG Ondansetron

Study Locations (1)

New York

  • SUNY Downstate University Hospital of Brooklyn - Brooklyn

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2021-01-01
Est. Completion 2023-07-01
Phase Phase 4

What the Registry Record Tells You About NCT05439772

The ClinicalTrials.gov registry entry for NCT05439772 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (97% lower). The listed sponsor is State University of New York - Downstate Medical Center, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Weight Loss appearing as the primary indexed condition, and to 1 intervention - of which Ondansetron is the first listed.

NCT05439772 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05439772 about?

NCT05439772 is a clinical study titled "Examining the Effect of Ondansetron on Bowel Prep Success". This is a pilot randomized-controlled trial assessing the utility of ondansetron for improving pediatric pre-colonoscopy bowel prep outcomes using the boston bowel preparation score, as well as assessing the impact on patient experience of bowel preparation.

What is the current status of trial NCT05439772?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2021-01-01. Estimated completion is 2023-07-01.

What conditions does trial NCT05439772 study?

This clinical trial studies the following conditions: Weight Loss, Inflammatory Bowel Diseases, Diarrhea, Abdominal Pain, Eosinophilic Gastroenteritis.

What interventions are being tested in trial NCT05439772?

The interventions under investigation include: Ondansetron (DRUG).

Who is sponsoring clinical trial NCT05439772?

This trial is sponsored by State University of New York - Downstate Medical Center, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05439772 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Weight Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.